BIONXT REPORTS ON NEW CLADRABINE ODF PRODUCT DEVELOPMENT AND COMMERCIALIZATION PROGRAM
Nov 15, 2023
VANCOUVER, BC – November 15, 2023 ‐ BioNxt Solutions Inc. (“BioNxt” or the “Company”) (CSE: BNXT / OTCQB: BNXTF / FSE: BXT) is pleased to...
BIONXT SIGNS DEFINITIVE AGREEMENT FOR 100% ACQUISITION OF IP AND CO-DEVELOPMENT OF CLADRIBINE ODF DRUG REFORMULATION FOR THE TREATMENT OF MULTIPLE SCLEROSIS
Nov 13, 2023
VANCOUVER, BC – November 13, 2023 ‐ BioNxt Solutions Inc. (“BioNxt” or the “Company”) (CSE: BNXT / OTCQB: BNXTF / FSE: BXT) is pleased to...
BIONXT SIGNS LOI FOR ACQUISITION OF IP AND CO-DEVELOPMENT OF ODF DRUG REFORMULATION FOR NEURODEGENERATIVE DISEASE
Aug 2, 2023
VANCOUVER, BC – August 2, 2023 ‐ BioNxt Solutions Inc. (“BioNxt” or the “Company”) (CSE: BNXT / OTC: BNXTF / FSE: BXT) is pleased to...
BIONXT RECEIVES APPROVAL FOR EUROPEAN CLINICAL STUDYOF TRANSDERMAL ROTIGOTINE PATCH FOR PARKINSON’S DISEASE
May 15, 2023
VANCOUVER, BC – May 15, 2023 ‐ BioNxt Solutions Inc. (“BioNxt” or the “Company”) (CSE: BNXT / OTC: BNXTF / FSE: BXT) is pleased to...
BIONXT SUCCESSFULLY COMPLETES PILOT STUDY FOR CONTRACT DEVELOPMENT CUSTOMER
May 9, 2023
VANCOUVER, BC – May 9, 2023 ‐ BioNxt Solutions Inc. (“BioNxt” or the “Company”) (CSE: BNXT / OTC: BNXTF / FSE: BXT) is pleased to...
BIONXT SECURES CONTRACT TO DEVELOP AND MANUFACTURE ODF PRODUCT FOR INTERNATIONAL PHARMACEUTICAL COMPANY
Apr 24, 2023
VANCOUVER, BC – April 24, 2023 ‐ BioNxt Solutions Inc. (“BioNxt” or the “Company”) (CSE: BNXT / OTC: BNXTF / FSE: BXT) is pleased to...
BIONXT ACQUIRES COMMERCIAL COATING AND CUTTING EQUIPMENT TO BUILD OUT EUROPEAN COMMERCIAL MANUFACTURING CAPACITY
Apr 17, 2023
VANCOUVER, BC – April 17, 2023 ‐ BioNxt Solutions Inc. (“BioNxt” or the “Company”) (CSE: BNXT / OTC: BNXTF / FSE: BXT) is pleased to...
BIONXT SOLUTIONS ACQUIRES NOVEL PRECISION DRUG COATING AND DELIVERY TECHNOLOGY
Mar 7, 2023
VANCOUVER, BC – March 07, 2023 ‐ BioNxt Solutions Inc. (“BioNxt” or the “Company”) (CSE: BNXT / OTC: BNXTF / FSE: BXT) is pleased to...
BIONXT SIGNS CLINICAL STUDY AGREEMENT AND COMMENCES MANUFACTURE OF CLINICAL SAMPLES FOR STUDY OF TRANSDERMAL ROTIGOTINE PATCH FOR PARKINSON’S DISEASE
Mar 1, 2023
VANCOUVER, BC – March 1, 2023 ‐ BioNxt Solutions Inc. (“BioNxt” or the “Company”) (CSE: BNXT / OTC: BNXTF / FSE: BXT) is pleased to...
BIONXT REPORTS UPDATE ON COMMERCIALIZATION OF ROTIGOTINE PATCH FOR TREATMENT OF PARKINSON’S DISEASE
Feb 13, 2023
VANCOUVER, BC – February 13, 2023 ‐ BioNxt Solutions Inc. (“BioNxt” or the “Company”) (CSE: BNXT / OTC: BNXTF / FSE: BXT) is pleased to...
XPhyto reports excellent Rotigotine in-vitro/ex-vivo results for Parkinson’s disease treatment
Oct 18, 2022
Vancouver, Canada, and Uttenweiler, Germany (October 18, 2022) - XPhyto Therapeutics Corp. (CSE:XPHY / OTC:XPHYF / FSE:4XT) (“XPhyto” or the “Company”) is pleased to report...
XPhyto completes Rotigotine transdermal patch optimization and comparative skin absorption study
Oct 11, 2022
Vancouver, Canada, and Uttenweiler, Germany (October 11, 2022) - XPhyto Therapeutics Corp. (CSE:XPHY / OTC:XPHYF / FSE:4XT) (“XPhyto” or the “Company”) is pleased to provide...
